Stock Analiz

Minerva Neurosciences, Inc. NERV

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$2.30Market cap $115M
Open the interactive analysis →

Minerva Neurosciences, Inc. (NERV) is a healthcare company listed in the US with a market value of about $115M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -549%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.

About Minerva Neurosciences

Minerva Neurosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 2 of the last 10 years in our data. Its share count rose by 58% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−77%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-549.0%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——$0$0$0$41M$0$0$0—
Net income-$293M$1M-$30M-$32M-$50M$2M-$72M-$50M-$32M-$31M
Free cash flow———-$25M————$3M—
EPS (diluted)$-34.67$0.19$-4.61$-6.01$-9.35$0.40$-14.80$-10.32$-6.64$-7.92
Net margin—————4.7%————
ROIC————-549.0%2.8%-262.2%-57.3%-23.4%-26.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Minerva Neurosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Minerva Neurosciences pay a dividend?

Not currently.

Is Minerva Neurosciences a good stock to buy?

We do not give buy or sell advice. Minerva Neurosciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.